U.S. pharma large copyright scrapped two experimental weight loss pills past year—a as soon as-day-to-day tablet, lotiglipron, on account of elevated liver enzymes as well as a twice-day by day tablet, danuglipron, because of potent Unintended effects—but CEO Albert Bourla has report